BRIEF-AstraZeneca Updates On Calquence Head-To-Head Results Versus Ibrutinib

AstraZeneca PLC: * ASTRAZENECA PLC - CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB

* ASTRAZENECA - CALQUENCE DEMONSTRATED FEWER INCIDENCES OF ATRIAL FIBRILLATION VERSUS IBRUTINIB * ASTRAZENECA - LONG-TERM FOLLOW UP FROM ELEVATE-TN TRIAL IN FRONT-LINE SETTING SHOWED CALQUENCE MAINTAINED PROGRESSION-FREE SURVIVAL

* ASTRAZENECA - FINAL RESULTS FROM HEAD-TO-HEAD ELEVATE-RR PHASE III TRIAL OF CALQUENCE DEMONSTRATED NON-INFERIOR PROGRESSION-FREE SURVIVAL Source text for Eikon: Further company coverage:

Also Read: BRIEF-AstraZeneca Plc Announces EUR 800M Bond Offering

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)